메뉴 건너뛰기




Volumn 43, Issue 1, 2017, Pages 48-58

Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials

Author keywords

DPP 4 inhibitors; Meta analysis; Micro and macrovascular complications; Mortality; Randomized clinical trials; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR;

EID: 84994475820     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2016.09.005     Document Type: Article
Times cited : (81)

References (28)
  • 1
    • 79959936188 scopus 로고    scopus 로고
    • National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants
    • [1] Danaei, G., Finucane, M.M., Lu, Y., Singh, G.M., Cowan, M.J., Paciorek, C.J., et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 378 (2011), 31–40.
    • (2011) Lancet , vol.378 , pp. 31-40
    • Danaei, G.1    Finucane, M.M.2    Lu, Y.3    Singh, G.M.4    Cowan, M.J.5    Paciorek, C.J.6
  • 2
    • 2342466734 scopus 로고    scopus 로고
    • Global prevalence of diabetes: estimates for the year 2000 and projections for 2030
    • [2] Wild, S., Roglic, G., Green, A., Sicree, R., King, H., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004), 1047–1053.
    • (2004) Diabetes Care , vol.27 , pp. 1047-1053
    • Wild, S.1    Roglic, G.2    Green, A.3    Sicree, R.4    King, H.5
  • 3
    • 84925489733 scopus 로고    scopus 로고
    • Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • [3] Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58 (2015), 429–442.
    • (2015) Diabetologia , vol.58 , pp. 429-442
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3    Diamant, M.4    Ferrannini, E.5    Nauck, M.6
  • 4
    • 0036158954 scopus 로고    scopus 로고
    • Biological actions and therapeutic potential of the glucagon-like peptides
    • [4] Drucker, D.J., Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122 (2002), 531–544.
    • (2002) Gastroenterology , vol.122 , pp. 531-544
    • Drucker, D.J.1
  • 5
    • 34447267513 scopus 로고    scopus 로고
    • Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis
    • [5] Amori, R.E., Lau, J., Pittas, A.G., Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298 (2007), 194–206.
    • (2007) JAMA , vol.298 , pp. 194-206
    • Amori, R.E.1    Lau, J.2    Pittas, A.G.3
  • 6
  • 7
    • 34250212715 scopus 로고    scopus 로고
    • Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    • [7] Nissen, S.E., Wolski, K., Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007), 2457–2471.
    • (2007) N Engl J Med , vol.356 , pp. 2457-2471
    • Nissen, S.E.1    Wolski, K.2
  • 8
    • 85011268105 scopus 로고    scopus 로고
    • Center for Drug Evaluation and Research (CDER). Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes
    • [8] U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008.
    • (2008)
    • U.S. Department of Health and Human Services, Food and Drug Administration,1
  • 9
    • 84902545306 scopus 로고    scopus 로고
    • Effects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: what is the level of evidence?
    • [9] Boussageon, R., Gueyffier, F., Cornu, C., Effects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: what is the level of evidence?. Diabetes Metab 40 (2014), 169–175.
    • (2014) Diabetes Metab , vol.40 , pp. 169-175
    • Boussageon, R.1    Gueyffier, F.2    Cornu, C.3
  • 10
    • 84944800184 scopus 로고    scopus 로고
    • Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
    • [10] Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
    • (2015) N Engl J Med , vol.373 , pp. 2117-2128
    • Zinman, B.1    Wanner, C.2    Lachin, J.M.3    Fitchett, D.4    Bluhmki, E.5    Hantel, S.6
  • 12
    • 84902551303 scopus 로고    scopus 로고
    • Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal
    • [12] Scheen, A.J., Charbonnel, B., Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. Diabetes Metab 40 (2014), 176–185.
    • (2014) Diabetes Metab , vol.40 , pp. 176-185
    • Scheen, A.J.1    Charbonnel, B.2
  • 13
    • 79959559653 scopus 로고    scopus 로고
    • Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1–based therapies
    • [13] Elashoff, M., Matveyenko, A.V., Gier, B., Elashoff, R., Butler, P.C., Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1–based therapies. Gastroenterology 141 (2011), 150–156.
    • (2011) Gastroenterology , vol.141 , pp. 150-156
    • Elashoff, M.1    Matveyenko, A.V.2    Gier, B.3    Elashoff, R.4    Butler, P.C.5
  • 15
    • 84874631463 scopus 로고    scopus 로고
    • GLP-1 based agents and acute pancreatitis: drug safety falls victim to the three monkey paradigm
    • [15] Gale, E.A., GLP-1 based agents and acute pancreatitis: drug safety falls victim to the three monkey paradigm. BMJ, 346, 2013, f1263, 10.1136/bmj.f1263.
    • (2013) BMJ , vol.346 , pp. f1263
    • Gale, E.A.1
  • 16
    • 84901926135 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials
    • [16] Monami, M., Dicembrini, I., Mannucci, E., Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 24 (2014), 689–697.
    • (2014) Nutr Metab Cardiovasc Dis , vol.24 , pp. 689-697
    • Monami, M.1    Dicembrini, I.2    Mannucci, E.3
  • 17
    • 84960100350 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
    • [17] Li, L., Li, S., Deng, K., Liu, J., Vandvik, P.O., Zhao, P., et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ, 352, 2016, i610, 10.1136/bmj.i610.
    • (2016) BMJ , vol.352 , pp. i610
    • Li, L.1    Li, S.2    Deng, K.3    Liu, J.4    Vandvik, P.O.5    Zhao, P.6
  • 18
    • 84930085787 scopus 로고    scopus 로고
    • Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
    • [18] Zannad, F., Cannon, C.P., Cushman, W.C., Bakris, G.L., Menon, V., Perez, A.T., et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385 (2015), 2067–2076.
    • (2015) Lancet , vol.385 , pp. 2067-2076
    • Zannad, F.1    Cannon, C.P.2    Cushman, W.C.3    Bakris, G.L.4    Menon, V.5    Perez, A.T.6
  • 19
    • 84928699536 scopus 로고    scopus 로고
    • Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials
    • May
    • [19] Udell, J.A., Cavender, M.A., Bhatt, D.L., Chatterjee, S., Farkouh, M.E., Scirica, B.M., Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 3 (2015 May), 356–366.
    • (2015) Lancet Diabetes Endocrinol , vol.3 , pp. 356-366
    • Udell, J.A.1    Cavender, M.A.2    Bhatt, D.L.3    Chatterjee, S.4    Farkouh, M.E.5    Scirica, B.M.6
  • 20
    • 34548603259 scopus 로고    scopus 로고
    • Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review
    • [20] Eurich, D.T., McAlister, F.A., Blackburn, D.F., Majumdar, S.R., Tsuyuki, R.T., Varney, J., et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. Brit Med J, 335(7618), 2007, 497.
    • (2007) Brit Med J , vol.335 , Issue.7618 , pp. 497
    • Eurich, D.T.1    McAlister, F.A.2    Blackburn, D.F.3    Majumdar, S.R.4    Tsuyuki, R.T.5    Varney, J.6
  • 21
    • 0016251063 scopus 로고
    • Role of diabetes in congestive heart failure: the Framingham study
    • [21] Kannel, W.B., Hjortland, M., Castelli, W.P., Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34 (1974), 29–34.
    • (1974) Am J Cardiol , vol.34 , pp. 29-34
    • Kannel, W.B.1    Hjortland, M.2    Castelli, W.P.3
  • 22
    • 0029893241 scopus 로고    scopus 로고
    • Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry
    • [22] Shindler, D.M., Kostis, J.B., Yusuf, S., Quinones, M.A., Pitt, B., Stewart, D., et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 77 (1996), 1017–1020.
    • (1996) Am J Cardiol , vol.77 , pp. 1017-1020
    • Shindler, D.M.1    Kostis, J.B.2    Yusuf, S.3    Quinones, M.A.4    Pitt, B.5    Stewart, D.6
  • 23
    • 0035810983 scopus 로고    scopus 로고
    • Glycemic control and heart failure among adult patients with diabetes
    • [23] Iribarren, C., Karter, A.J., Go, A.S., Ferrara, A., Liu, J.Y., Sidney, S., et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 103 (2001), 2668–2673.
    • (2001) Circulation , vol.103 , pp. 2668-2673
    • Iribarren, C.1    Karter, A.J.2    Go, A.S.3    Ferrara, A.4    Liu, J.Y.5    Sidney, S.6
  • 25
    • 45149133036 scopus 로고    scopus 로고
    • Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes (ADVANCE)
    • [25] Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes (ADVANCE). N Engl J Med 358 (2008), 2560–2572.
    • (2008) N Engl J Med , vol.358 , pp. 2560-2572
  • 26
    • 79960959816 scopus 로고    scopus 로고
    • Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
    • [26] Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassaï, B., et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. Brit Med J, 343, 2011, d4169, 10.1136/bmj.d4169.
    • (2011) Brit Med J , vol.343 , pp. d4169
    • Boussageon, R.1    Bejan-Angoulvant, T.2    Saadatian-Elahi, M.3    Lafont, S.4    Bergeonneau, C.5    Kassaï, B.6
  • 27
    • 84898614282 scopus 로고    scopus 로고
    • Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial
    • [27] Lincoff, A.M., Tardif, J.C., Schwartz, G.G., et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA 311 (2014), 1515–1525.
    • (2014) JAMA , vol.311 , pp. 1515-1525
    • Lincoff, A.M.1    Tardif, J.C.2    Schwartz, G.G.3
  • 28
    • 84946191506 scopus 로고    scopus 로고
    • Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes?
    • [28] Bejan-Angoulvant, T., Cornu, C., Archambault, P., Tudrej, B., Audier, P., Brabant, Y., et al. Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes?. Diabetes Metab 41 (2015), 195–201.
    • (2015) Diabetes Metab , vol.41 , pp. 195-201
    • Bejan-Angoulvant, T.1    Cornu, C.2    Archambault, P.3    Tudrej, B.4    Audier, P.5    Brabant, Y.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.